Comparison of adverse drug reaction profiles of two tacrolimus formulations in rats

Immunopharmacology and Immunotoxicology

Volumn 34, Issue 3, 2012, Pages 434-442

  Hwang, Hyeonseok ^a   Ghee, Jung Yeon ^a   Song, Ji Hyun ^a   Piao, Shangguo ^a   Yang, Chul Woo ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Diabetes mellitus; Hepatotoxicity; Nephrotoxicity; Tacrolimus; Transplantation

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; TACROBELL; TACROLIMUS; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHRONIC TOXICITY; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETES MELLITUS; DIABETOGENESIS; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; KIDNEY DYSFUNCTION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; LIVER FUNCTION; LIVER INJURY; LIVER TOXICITY; MALE; NEPHROTOXICITY; NONHUMAN; PANCREAS FUNCTION; PANCREAS INJURY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; URINALYSIS;

ANIMALS; DIABETES MELLITUS; DRUG-INDUCED LIVER INJURY; DRUGS, GENERIC; FIBROSIS; INSULIN-SECRETING CELLS; KIDNEY DISEASES; MALE; PANCREATIC DISEASES; RATS; RATS, SPRAGUE-DAWLEY; TACROLIMUS;

RATTUS;

EID: 84860718095     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2011.618135     Document Type: Article

References (31)

1. Ekberg, H., Tedesco-Silva, H., Demirbas, A., Vítko, S., Nashan, B., Gürkan, A., Margreiter, R., Hugo, C., Grinyó, J.M., Frei, U., Vanrenterghem, Y., Daloze, P., Halloran, P.F.; ELITE-Symphony Study. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007, 357, 2562-2575. (Pubitemid 350294223)
2. Webster, A.C., Woodroffe, R.C., Taylor, R.S., Chapman, J.R., Craig, J.C. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and metaregression of randomised trial data. BMJ 2005, 331, 810.
3. Kim B., Huh W., Kim M.O., Yeo H.M., Kim H.J., Kim J.A., et al. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients. Korean J Nephrol 2004, 23, 785-792.
4. Ekberg, H., Bernasconi, C., Nöldeke, J., Yussim, A., Mjörnstedt, L., Erken, U., Ketteler, M., Navrátil, P. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010, 25, 2004-2010.
5. Ligtenberg, G., Hené, R.J., Blankestijn, P.J., Koomans, H.A. Cardiovascular risk factors in renal transplant patients: Cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001, 12, 368-373. (Pubitemid 32116380)
6. Tamura, K., Fujimura, T., Tsutsumi, T., Nakamura, K., Ogawa, T., Atumaru, C., Hirano, Y., Ohara, K., Ohtsuka, K., Shimomura, K. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic β-cell. Transplantation 1995, 59, 1606-1613.
7. Penfornis, A., Kury-Paulin, S. Immunosuppressive drug-induced diabetes. Diabetes Metab 2006, 32, 539-546. (Pubitemid 44836987)
8. Ahn, H.Y., Cho, Y.M., Yi, N.J., Suh, K.S., Lee, K.U., Park, K.S., Kim, S.Y., Lee, H.K. Predictive factors associated with the reversibility of post-transplantation diabetes mellitus following liver transplantation. J Korean Med Sci 2009, 24, 567-570.
9. Park, K., Kim, Y.S., Kwon, K.I., Park, M.S., Lee, Y.J., Kim, K.H. A randomized, open-label, two-period, crossover bioavailability study of two oral formulations of tacrolimus in healthy Korean adults. Clin Ther 2007, 29, 154-162. (Pubitemid 46414035)
10. Kim, S.J., Huh, K.H., Han, D.J., Moon, I.S., Kim, S.J., Kim, Y.L., Kim, H.C., Lee, S., Kang, C.M., Cho, B.H., Kim, Y.S. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation. Transplant Proc 2009, 41, 1671-1674.
11. Miura, M., Satoh, S., Niioka, T., Kagaya, H., Saito, M., Hayakari, M., Habuchi, T., Suzuki, T. Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients. Ther Drug Monit 2008, 30, 52-59. (Pubitemid 351161099)
12. Petan, J.A., Undre, N., First, M.R., Saito, K., Ohara, T., Iwabe, O., Mimura, H., Suzuki, M., Kitamura, S. Physiochemical properties of generic formulations of tacrolimus in Mexico. Transplant Proc 2008, 40, 1439-1442. (Pubitemid 351853144)
13. Shihab, F.S., Bennett, W.M., Tanner, A.M., Andoh, T.F. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 1997, 64, 1829-1837. (Pubitemid 28041725)
14. Yamauchi, A., Oishi, R., Kataoka, Y. Tacrolimus-induced neurotoxicity and nephrotoxicity is ameliorated by administration in the dark phase in rats. Cell Mol Neurobiol 2004, 24, 695-704. (Pubitemid 39062431)
15. Ninova, D., Covarrubias, M., Rea, D.J., Park, W.D., Grande, J.P., Stegall, M.D. Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: Differential intragraft expression of transforming growth factor-β1 and α-smooth muscle actin. Transplantation 2004, 78, 338-344. (Pubitemid 39095398)
16. Li, F., Li, Q. Effects of different dose of FK506 on endocrine function of pancreatic islets and damage of β cells of pancreatic islets in a Wistar rat model. Immunopharmacol Immunotoxicol 2010, 32, 333-338.
17. Li, Q.Y., Li, F., Sun, J.H., Chi, Y.Y., Yin, H.S., Liu, S.Q., Mei, Y.H. Mechanisms of diabetes mellitus induced with FK506 in SD rats models. Immunopharmacol Immunotoxicol 2009, 31, 675-681.
18. Han, D.H., Piao, S.G., Song, J.H., Ghee, J.Y., Hwang, H.S., Choi, B.S., Kim, J., Yang, C.W. Effect of sirolimus on calcineurin inhibitorinduced nephrotoxicity using renal expression of KLOTHO, an antiaging gene. Transplantation 2010, 90, 135-141.
19. Mollison, K.W., Fey, T.A., Krause, R.A., Andrews, J.M., Bretheim, P.T., Cusick, P.K., Hsieh, G.C., Luly, J.R. Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models. Toxicology 1998, 125, 169-181. (Pubitemid 28162644)
20. Song, H.K., Han, D.H., Song, J.H., Ghee, J.Y., Piao, S.G., Kim, S.H., Yoon, H.E., Li, C., Kim, J., Yang, C.W. Influence of sirolimus on cyclosporine-induced pancreas islet dysfunction in rats. Am J Transplant 2009, 9, 2024-2033.
21. Chung, B.H., Li, C., Sun, B.K., Lim, S.W., Ahn, K.O., Yang, J.H., Choi, Y.H., Yoon, K.H., Sugawara, A., Ito, S., Kim, J., Yang, C.W. Rosiglitazone protects against cyclosporine-induced pancreatic and renal injury in rats. Am J Transplant 2005, 5, 1856-1867. (Pubitemid 41039858)
22. Giessler, G.A., Gades, N.M., Friedrich, P.F., Bishop, A.T. Severe tacrolimus toxicity in rabbits. Exp Clin Transplant 2007, 5, 590-595. (Pubitemid 47261587)
23. Finn, W.F. FK506 nephrotoxicity. Ren Fail 1999, 21, 319-329. (Pubitemid 29318198)
24. Stillman, I.E., Andoh, T.F., Burdmann, E.A., Bennett, W.M., Rosen, S. FK506 nephrotoxicity: Morphologic and physiologic characterization of a rat model. Lab Invest 1995, 73, 794-803. (Pubitemid 26002338)
25. Naesens, M., Kuypers, D.R., Sarwal, M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009, 4, 481-508.
26. Sanchez-Campos, S., Lopez-Acebo, R., Gonzalez, P., Culebras, J.M., Tuñon, M.J., Gonzalez-Gallego, J. Cholestasis and alterations of glutathione metabolism induced by tacrolimus (FK506) in the rat. Transplantation 1998, 66, 84-88. (Pubitemid 28341172)
27. Ganschow, R., Albani, J., Grabhorn, E., Richter, A., Burdelski, M. Tacrolimus-induced cholestatic syndrome following pediatric liver transplantation and steroid-resistant graft rejection. Pediatr Transplant 2006, 10, 220-224.
28. Farghali, H., Sakr, M., Gasbarrini, A., Venkataramanan, R., Gavaler, J., Starzl, T.E., Van Thiel, D.H. Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. Transplant Proc 1991, 23, 2802-2804.
29. Mitamura, T., Yamada, A., Hanaoka, K., Asano, M., Niwa, T., Seki, J. Effect of pharmacokinetic profile on the pancreatic toxicity and efficacy of tacrolimus in rats. J Toxicol Sci 2008, 33, 575-584.
30. Nam, J.H., Mun, J.I., Kim, S.I., Kang, S.W., Choi, K.H., Park, K., Ahn, C.W., Cha, B.S., Song, Y.D., Lim, S.K., Kim, K.R., Lee, H.C., Huh, K.B. β-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 2001, 71, 1417-1423. (Pubitemid 32507115)
31. Bugliani, M., Masini, M., Liechti, R., Marselli, L., Xenarios, I., Boggi, U., Filipponi, F., Masiello, P., Marchetti, P. The direct effects of tacrolimus and cyclosporin A on isolated human islets: A functional, survival and gene expression study. Islets 2009, 1, 106-110.